DDR on DTC: Humira

Share this article:
Deborah Dick-Rath
Deborah Dick-Rath

I have commented before on AbbVie's successful marketing approach for their Humira franchise—and once again attention must be paid. This time, they are firing on all of DTC's cylinders to educate and convert Crohn's Disease sufferers to their brand.

Very informative “unbranded” :30 commercials touch on the anxiety of Crohn's sufferers in managing their symptoms. The “What If?” tagline reflects how this anxiety is exacerbated by the warning that the disease could lead to harm if untreated. The spots direct sufferers to go online and to talk to a doctor “for answers.” Nicely produced, with just a little bit of scariness.

The Humira branded :60 spots speak to diagnosed patients who are reminded to talk with their gastroenterologist. These spots end on a remarkable message of hope, “Remission is Possible.”

There is nothing fancy here. In fact, the “urgent” cues in the unbranded spot reminded me of effective problem-solution OTC ads. The branded spots are typically loaded with Fair Balance while we watch a “relieved” patient enjoying life. However, what makes this campaign great is the way that Humira links the advantages of the unbranded commercial to find and educate sufferers with the branded campaign. All commercials leverage the same anxiety over disease symptoms. In this way, AbbVie has stepped up and taken the lead—and their brand will be the beneficiary. Yet another notch in the belt of the Humira franchise.


Deborah Dick-Rath is the president of Epic Proportions, a healthcare communications consultancy. She can be reached at deborahdrath@optonline.net

Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.